A billion-dollar real estate project is coming to Morrisville, North Carolina, as developers hope to capitalize on the growing biotechnology industry in the state’s Research Triangle.

Vincent Colicchio – Vice President, Supply Chain and External Manufacturing for Dr. Reddy’s Laboratories – discusses supply chain, manufacturing and training issues pertaining to generic drug manufacturing.

BioNTech, Moderna and Johnson & Johnson are working on vaccines that specifically target Omicron in case their existing shots are not effective against the new coronavirus variant, the companies said on November 29.

CVS Health Corp. will shut about 900 stores over the next three years as the company tries to adapt to changing consumer preferences by pivoting to new store formats that offer more health services.

Philips, the medical equipment maker that is recalling ventilators due to use of parts containing a potentially hazardous foam, said on November 14 the company is in discussions with U.S. regulators after a new inspection of one of its facilities.

Merck

Merck & Co. signed a licensing agreement with the United Nations-backed Medicines Patent Pool (MPP) that will allow more companies to manufacture generic versions of the company’s experimental oral antiviral Covid-19 treatment, the U.S. drugmaker and the organization announced on Oct. 27.

The second part of the 2021 CPhI Annual Report looks ahead to predict the pharma manufacturing, therapeutic and technology environment in 2030.

Pfizer, Moderna, and AstraZeneca have been running “dress rehearsals” by adapting their current formulations of Covid-19 vaccines to match present known SARS-CoV-2 variants.

Novavax

Shares of Novavax Inc. fell 16 percent after a report from Politico said the company faces significant hurdles in proving it can manufacture the experimental Covid-19 vaccine NVX-CoV2373 that meets regulators’ quality standards, resulting in production delays.

Bayer terminated a vaccine manufacturing partnership under which the company would have helped produce CureVac’s Covid-19 shot, a spokesperson for Bayer told a German newspaper.